


## nivasorexant OX1R

orexin-1 receptor antagonist  
Ph. II for binge-eating disorder  
opt. from a previously disclosed DORA  
*J. Med. Chem.*, February 2024


ACTELION PHARMACEUTICALS, ALLSCHWIL, CH



## ACT-1016-0707 LPAR1

LPAR1 antagonist  
preclinical for fibrotic diseases  
SAR opt. from an LPAR1  $\beta$ -arrestin recruitment-based HTS hit  
*J. Med. Chem.*, February 2024


IDORSIA PHARMACEUTICALS, ALLSCHWIL, CH



## CT1812 S2R

brain-penetrant S2R modulator  
Ph. II for dementia with Lewy bodies, Alzheimer's disease, and age-related macular degeneration  
from an unbiased phenotypic neuronal trafficking assay  
*bioRxiv*, February 2024


COGNITION THERAPEUTICS, PITTSBURGH, PA



## AZD1390 ATM

brain-penetrant ATM inhibitor  
Ph. I for solid tumors and glioblastoma  
BBB-penetrance enhancement focused opt. starting from AZD0156  
*J. Med. Chem.*, February 2024


ASTRAZENECA, CAMBRIDGE, UK



## TYA-018 HDAC6

HDAC6 inhibitor  
preclinical for heart failure with preserved ejection fraction  
from 5,500-cmpd. phenotypic screen and iPSC-CM trained deep learning model  
*Nat. Commun.*, February 2024


TENAYA THERAPEUTICS, CA



## NT-0249 NLRP3

peripherally restricted NLRP3 inflammasome inhibitor  
Ph. I single ascending dose study  
discovery undisclosed  
*J. Pharmacol. Exp. Ther.*, February 2024


NODTHERA, CAMBRIDGE, UK



## NX-2127 BTK

BTK degrader  
Ph. I for relapsed/refractory B-cell malignancies  
BTK binder structure opt. from NRX-0492  
*J. Med. Chem.*, February 2024


NURIX THERAPEUTICS, SAN FRANCISCO, CA



## BAY-9835 ADAMTS7

ADAMTS7 inhibitor  
preclinical for atherosclerosis  
from 6,025-cmpd. virtual amide library screening, and selectivity/DMPK opt.  
*J. Med. Chem.*, February 2024


BAYER AG, WUPPERTAL, DE



## cilofexor FXR

FXR agonist  
Ph. III for primary sclerosing cholangitis  
from opt. of a previous clinical candidate to mitigate liver toxicity  
*JPET*, February 2024

PHENEX, HEIDELBERG, DE / GILEAD, CA



## compound 17 CDK2

CDK2 inhibitor  
preclinical for oncology  
from HTS of internal library collection and isoform selectivity opt.  
*J. Med. Chem.*, February 2024

INCYTE CORPORATION, WILMINGTON, DE